← BLACKLEDGER Content Feed

Selling • NEUROPHAGE x BLACKLEDGER • 8 min read • 2026-10-14

BLACKLEDGER Selling Watch: VKTX, CRSP, ABOS

BLACKLEDGERMarket ResearchSellingVKTXCRSPABOSUEC
BLACKLEDGER Selling public market research update for VKTX, CRSP, ABOS

BLACKLEDGER's latest selling watch update tracks VKTX, CRSP, ABOS, UEC, MARA, LCID from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.

Selling Watch Data

The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-10-14T08:00:05.682861+00:00.

Educational Context: How To Use This Page

This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.

VKTX Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Viking Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystr

Why VKTX Is In This Public Update

Outside Public Headlines / Source Notes

CRSP Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bear. Public tier: Extended.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog

Why CRSP Is In This Public Update

Outside Public Headlines / Source Notes

ABOS Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Acumen Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Why ABOS Is In This Public Update

Outside Public Headlines / Source Notes

UEC Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Uranium Energy Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.

Uranium Energy Corp., together with its subsidiaries, engages in the exploration, pre-extraction, extraction, and processing of uranium and titanium concentrates properties in the United States, Canada, and the Republic of Paraguay. Its principal projects are located in Wyoming and Texas in the United States, as well as in Saskatchewan, Canada. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. The company was incorporated in 2003 and is headquartered in Corpus Christi, Texas.

Why UEC Is In This Public Update

Outside Public Headlines / Source Notes

MARA Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: MARA Holdings, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

MARA Holdings, Inc. operates as an energy and digital infrastructure company in North America, the Middle East, Europe, and Latin America. The company leverages Bitcoin Mining and Artificial Intelligence compute to monetize excess energy and underutilized power, optimize power management across operations and support AI inference applications. The company was formerly known as Marathon Digital Holdings, Inc. and changed its name to MARA Holdings, Inc. in August 2024. MARA Holdings, Inc. was incorporated in 2010 and is based in Hallandale Beach, Florida.

Why MARA Is In This Public Update

Outside Public Headlines / Source Notes

LCID Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Lucid Group, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.

Lucid Group, Inc., a technology company, designs, develops, manufactures, and sells electric vehicles (EV), EV powertrains, and battery systems. The company provides Lucid Air sedan and Lucid Gravity SUV. It also designs and develops proprietary software in-house for Lucid vehicles. The company sells vehicles directly to consumers through its retail sales network and direct online sales, including Lucid Financial Services. It has a strategic partnership with Bolt to develop and deploy autonomous mobility services across Europe. The company is headquartered in Newark, California. Lucid Group, Inc. is a subsidiary of Ayar Third Investment Company.

Why LCID Is In This Public Update

Outside Public Headlines / Source Notes

What The Public Data Shows

The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.

Why This Category Matters

The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.

Research-Only Notice

BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.

Research-only. No execution signal. Not financial advice.